NASDAQ:ONCY Oncolytics Biotech Q2 2025 Earnings Report $1.29 +0.04 (+3.20%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$1.41 +0.12 (+9.22%) As of 05:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Oncolytics Biotech EPS ResultsActual EPS-$0.05Consensus EPS -$0.11Beat/MissBeat by +$0.06One Year Ago EPSN/AOncolytics Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncolytics Biotech Announcement DetailsQuarterQ2 2025Date8/8/2025TimeBefore Market OpensConference Call DateFriday, August 8, 2025Conference Call Time10:00AM ETUpcoming EarningsOncolytics Biotech's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Oncolytics Biotech Earnings HeadlinesOncolytics Biotech Inc. (NASDAQ:ONCY) Receives $5.00 Average Target Price from AnalystsSeptember 21, 2025 | americanbankingnews.comResearch Analysts Offer Predictions for ONCY Q3 EarningsSeptember 19, 2025 | americanbankingnews.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world. | Traders Agency (Ad)Oncolytics Biotech Expands GOBLET Study to U.S., Shows Promising ResultsSeptember 16, 2025 | msn.comOncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site ExpansionSeptember 16, 2025 | prnewswire.comLake Street Keeps Their Buy Rating on Oncolytics Biotech (ONCY)September 10, 2025 | theglobeandmail.comSee More Oncolytics Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncolytics Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncolytics Biotech and other key companies, straight to your email. Email Address About Oncolytics BiotechOncolytics Biotech (NASDAQ:ONCY) (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors. Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers. Collaborations with academic centers and pharmaceutical partners support ongoing research into optimal dosing regimens, novel combination strategies and biomarker identification. The company also maintains an early-stage pipeline of additional viral candidates aimed at broadening its platform of immune‐activating cancer therapies. Headquartered in Calgary, Alberta, with a research and development facility in Houston, Texas, Oncolytics sustains a presence in major North American life science hubs. The company’s infrastructure supports integrated translational research, process development and global clinical trial management, with a focus on advancing regulatory filings and securing strategic partnerships to accelerate commercialization. Under the leadership of President and Chief Executive Officer Brad Thompson, Oncolytics’ management team brings extensive experience in oncology drug development, virology and biopharmaceutical operations. The company remains committed to advancing its viral immunotherapy platform through rigorous clinical investigation and collaborative programs designed to address unmet needs in oncology.View Oncolytics Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO Bulls Upcoming Earnings NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
